No single ticker was named. Biotech ETFs are one way for retail investors to get exposure. Not a recommendation.
Canara Biotech's low-CapEx growth via distressed asset
The bull thesis for Canara Biotech centers on its acquisition of a world-class production facility at a 90% discount, enabling low-CapEx capacity expansion into growing cannabis demand.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.